

Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1	Name of the Target Company (TC)	GlaxoSmithKline Consumer Healthcare Limited		
2	Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Arisaig Partners (Asia) Pte. Ltd (FII), c/o Arisaig India Fund Limited		
3	Whether the acquirer belongs to Promoter/Promoter group	No		
4	Name(s) of the Stock Exchange(s) where the shares of TC are Listed	Bombay Stock Exchange Limited National Stock Exchange of India Limited		
5	Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable	% w.r.t. total diluted share/voting capital of the TC (*)
	Before the acquisition/disposal under consideration, holding of :			
	a) Shares carrying voting rights	2,106,101	5.01%	-
	b) Voting rights (VR) otherwise than by shares	-	-	-
	c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	-	-	-
	Total (a+b+c)	2,106,101	5.01%	-
	Details of acquisition / sale			
	a) Shares carrying voting rights acquired/sold	6,897	0.02%	-
	b) VRs acquired /sold otherwise than by shares	-	-	-
	c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) sold	-	-	-
	Total (a+b+c)	6,897	0.02%	-
	After the acquisition / sale, holding of:			
	a) Shares carrying voting rights	2,099,204	4.99%	-
	b) VRs otherwise than by shares	-	-	-
	c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after sale.	-	-	-
	Total (a+b+c)	2,099,204	4.99%	-
6	Mode of acquisition / sale (e.g. open market / off-market / public issue /rights issue / preferential allotment /inter-se transfer etc).	Open Market Sale		
7	Date of acquisition / sale of shares /VR or date of receipt of intimation of allotment of shares, whichever is applicable	11th June, 2013		
8	Equity share capital / total voting capital of the TC before the said acquisition / sale	5.01%		
9	Equity share capital/ total voting capital of the TC after the said acquisition / sale	4.99%		
10	Total diluted share/voting capital of the TC after the said acquisition/sale(*)	-		

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Place Singapore
Date 13 June 2013

For
Arisaig Partners (Asia) Pte Ltd

Director / Authorised Signatory

